The FDA approved Pluvicto for early-stage metastatic prostate cancer, a novel mRNA flu vaccine for adults over 50, and a new melanoma immunotherapy.

U.S. health regulators expanded approval for targeted prostate cancer treatment Pluvicto to early-stage metastatic cases, alongside new clearances for advanced melanoma immunotherapies and adult mRNA flu vaccines.

The Food and Drug Administration cleared Pluvicto for patients diagnosed with early-stage metastatic prostate cancer, broadening access to radioligand therapy designed to target specific cancer cells while sparing healthy surrounding tissue. The decision follows clinical evaluations measuring disease progression and patient response rates.

Former New York Knicks player Allan Houston launched a public health initiative addressing prostate cancer outcomes, emphasizing earlier screening and combined physical and mental healthcare strategies for diagnosed patients.

First mRNA flu vaccine authorized for older adults

Regulators authorized the first mRNA-based influenza vaccine specifically formulated for adults aged 50 and older. The platform uses messenger RNA technology to prompt immune responses against seasonal influenza strains, mirroring mechanisms deployed during pandemic response efforts.

Clinical data submitted to health authorities demonstrated sufficient antibody responses among older demographics, who face higher risks of severe complications and hospitalization from seasonal flu strains.

Advanced melanoma immunotherapy and pain management

The agency approved a new immunotherapy regimen for advanced melanoma. The treatment mechanism enhances the immune system's capacity to identify and destroy malignant melanoma cells in advanced stages where surgical intervention offers limited efficacy.

Separately, regulatory updates cleared a pain relief combination pairing acetaminophen with naproxen. The dual-action formulation provides up to 12 hours of continuous pain relief for inflammatory and systemic conditions.

Disparities in rare cardiovascular disease care

Clinical data highlights persistent treatment barriers in hereditary transthyretin amyloid cardiomyopathy, known as hATTR-CM. The progressive condition disproportionately affects individuals of African descent, prompting health advocates to push for earlier diagnostic screening and equitable care access.

Healthcare providers continue tracking long-term outcomes across newly approved treatment categories as clinical deployment begins nationwide.